BTIG analyst Kambiz Yazdi initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $50 price target Sionna Therapeutics is a clinical-stage biotech company developing therapies for the treatment of cystic fibrosis, the analyst tells investors in a research note. BTIG thinks SION-719 will meet benchmarks for its high-impact Phase 2a readout in mid-2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics: Promising Developments and Strategic Advancements Boost Price Target
- Sionna Therapeutics Advances CF Pipeline Amid Strong Financials
- Sionna Therapeutics reports Q3 EPS (46c), consensus (47c)
- Sionna Therapeutics expects cash to fund operations into 2028
- Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study